Skip to main content

GLP-3 Explained: Triple-Agonist Weight-Loss Drugs

Written by RobTatum on . Posted in Weight Loss.

When people search for “GLP-3,” they are usually referring to a new class of triple-agonist weight-loss medications.

There is no human hormone called GLP-3.

The term is internet shorthand for drugs designed to activate three metabolic receptors at the same time:

  • GLP-1
  • GIP
  • Glucagon

The most advanced example in this category is retatrutide, which is currently investigational and not FDA-approved.

Quick Overview

  • “GLP-3” is not a real hormone.
  • It typically refers to triple-agonist drugs targeting GLP-1, GIP, and glucagon receptors.
  • Retatrutide is the leading triple-agonist candidate in development.
  • In phase 2 clinical trials, the highest dose of retatrutide produced about 24 percent average weight loss at 48 weeks.
  • Retatrutide is still in clinical trials and not FDA-approved.

What Triple-Agonist Drugs Do

Triple-agonists are designed to stimulate three metabolic pathways simultaneously.

GLP-1 Receptor

  • Reduces appetite
  • Slows stomach emptying
  • Improves post-meal glucose control

This pathway is already used in approved medications such as semaglutide.

GIP Receptor

  • Influences insulin signaling
  • Works alongside GLP-1 to regulate appetite and metabolism

This pathway is part of tirzepatide’s mechanism.

Glucagon Receptor

  • May increase energy expenditure
  • Influences fat metabolism

Adding glucagon receptor activity is what distinguishes triple-agonists from dual-agonists.

The goal of combining all three is greater weight loss and broader metabolic effects.

What Research Shows So Far

In a phase 2 clinical trial in adults with obesity:

  • The highest dose of retatrutide led to approximately 24 percent average weight loss at 48 weeks.
  • Participants were still losing weight at the end of the study period.
  • Cardiometabolic markers such as blood pressure and lipids improved.
  • Many individuals with prediabetes returned to normal glucose levels.

These results are promising. However, they come from phase 2 trials. Larger phase 3 trials are ongoing.

Retatrutide remains investigational.

Side Effects Observed in Trials

The side effect pattern is similar to GLP-1-based medications.

Common Side Effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation

These symptoms were generally dose-related and more common during dose increases.

Heart Rate

Modest increases in resting heart rate were observed.

Gradual dose escalation was associated with better tolerability.

Comparison With Current Approved Medications

Here is a simplified overview based on published trial data.

GLP-1 Only (Example: Semaglutide 2.4 mg)

  • Mechanism: GLP-1 receptor activation
  • Reported average weight loss: Around 15 percent at 68 weeks
  • FDA-approved

Dual GIP/GLP-1 (Example: Tirzepatide)

  • Mechanism: GIP + GLP-1 receptor activation
  • Reported average weight loss: Up to about 22 percent at 72 weeks
  • FDA-approved

Triple GLP-1/GIP/Glucagon (Example: Retatrutide)

  • Mechanism: GLP-1 + GIP + glucagon receptor activation
  • Reported average weight loss: Up to about 24 percent at 48 weeks
  • Investigational

These numbers come from separate trials and are not direct head-to-head comparisons.

Regulatory Status and Access

Retatrutide is:

  • In phase 3 clinical trials
  • Not FDA-approved
  • Only available through clinical trials

Consumers should avoid products marketed online as retatrutide outside research settings. Counterfeit and unregulated products pose serious safety risks.

Body Composition During Weight Loss

Large weight loss from any method includes both:

  • Fat mass
  • Lean tissue

Research on GLP-1–based medications shows lean tissue can represent roughly 25–40 percent of total weight lost without resistance training and adequate protein intake.

This highlights the importance of:

  • Strength training
  • Adequate protein
  • Medical monitoring

The number on the scale does not tell the whole story.

Bottom Line

“GLP-3” refers to triple-agonist medications like retatrutide that target GLP-1, GIP, and glucagon receptors.

Early clinical trials show substantial weight loss potential. However, retatrutide is not FDA-approved and remains investigational.

Weight-loss medications should always be considered within a comprehensive plan that includes:

  • Nutrition
  • Resistance training
  • Medical supervision
  • Monitoring of body composition

If you are exploring advanced weight-loss therapies, consult a qualified healthcare provider to determine what is appropriate for your health profile.